Drug Profile

ELA 822

Alternative Names: ELA-822

Latest Information Update: 21 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Electra Therapeutics
Class Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; SIRPA protein inhibitors; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Autoimmune disorders

Most Recent Events

15 Aug 2026 Electra Therapeutics plans a phase I trial in Healthy volunteers in Austria in August 2026 (CTIS2025-524911-34-00)
12 Aug 2026 Phase-I clinical trials in Autoimmune disorders (In volunteers) in Austria (Parenteral) (CTIS2025-524911-34-00)
28 Mar 2026 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com